All In Biotech

Drug Trial Radar · NCT04773353

Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Indian Women

A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre Trial in India Comparing the Efficacy and Safety of FE 999049 (Follitropin Delta) With Follitropin Alfa (GONAL-F) in Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme

Last checked: Nov 19, 2026Latest source record: Jan 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

220

Actual

Start

Dec 3, 2021

Primary completion

Dec 12, 2023

Study completion Dec 12, 2023

Sponsor

Lead sponsor
Ferring PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Feb 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 21 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate non-inferiority of FE 999049 compared with GONAL-F with respect to ongoing pregnancy rate in women undergoing controlled ovarian stimulation.

Conditions

  • Infertility

Interventions

  • Follitropin Delta (FE 999049)Drug

    FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. For participants with low AMH (\<15 pmol/L) the daily FE 999049 dose was 12 μg, irrespective of body weight. For participants with high AMH (≥15 pmol/L) the daily FE 999049 dose was on a continuous scale ranging from 0.19 to 0.10 μg/kg, i.e. dependent on actual AMH and body weight. The daily FE 999049 dose was fixed throughout the stimulation period and maximum allowed daily dose was 12 μg. Participants could be treated for a maximum of 20 days.

  • Follitropin Alfa (GONAL-F)Drug

    GONAL-F was administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 450 IU. Participants could be treated for a maximum of 20 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ongoing pregnancy rateTime frame: 10-11 weeks after embryo transfer

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Ferring Investigational Site

    Bangalore, India

  • Ferring Investigational Site

    Kolhāpur, India

  • Ferring Investigational Site

    New Delhi, India

  • Ferring Investigational Site

    Ahmedabad, Gujarat, India

  • Ferring Investigational Site

    Anand, Gujarat, India

  • Ferring Investigational Site

    Nashik, Maharashtra, India

  • Ferring Investigational Site

    Pune, Mumbai, India

  • Ferring Investigational Site

    Varanasi, New Delhi, India

  • Ferring Investigational Site

    Chennai, Tamil Nadu, India

  • Ferring Investigational Site

    Coimbatore, Tamil Nadu, India

  • Ferring Investigational Site

    Secunderabad, Telangana, India

  • Ferring Investigational Site

    Lucknow, Uttar Pradesh, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.